2.11
-0.12(-5.38%)
Currency In USD
| Previous Close | 2.23 |
| Open | 2.25 |
| Day High | 2.31 |
| Day Low | 2.06 |
| 52-Week High | 622.5 |
| 52-Week Low | 2.05 |
| Volume | 145,757 |
| Average Volume | 352,961 |
| Market Cap | 1.59M |
| PE | -0.01 |
| EPS | -255.6 |
| Moving Average 50 Days | 3.85 |
| Moving Average 200 Days | 65.92 |
| Change | -0.12 |
If you invested $1000 in Conduit Pharmaceuticals Inc. (CDT) since IPO date, it would be worth $0.14 as of July 18, 2025 at a share price of $2.11. Whereas If you bought $1000 worth of Conduit Pharmaceuticals Inc. (CDT) shares 2 years ago, it would be worth $0.13 as of July 18, 2025 at a share price of $2.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
GlobeNewswire Inc.
Jul 08, 2025 12:30 PM GMT
Independent advisor appointed to assess feasibility and strategic benefit of a partial cryptocurrency-based treasury reserveInitiative aims to diversify capital positioning while retaining focus on IP-driven pharmaceutical development NAPLES, Fla. an
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
GlobeNewswire Inc.
Jul 07, 2025 12:30 PM GMT
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
GlobeNewswire Inc.
Jun 04, 2025 12:30 PM GMT
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Condui